The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
about
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The comparison of outcomes fro ...... ld-type or unknown EGFR status
@en
The comparison of outcomes fro ...... d-type or unknown EGFR status.
@nl
type
label
The comparison of outcomes fro ...... ld-type or unknown EGFR status
@en
The comparison of outcomes fro ...... d-type or unknown EGFR status.
@nl
prefLabel
The comparison of outcomes fro ...... ld-type or unknown EGFR status
@en
The comparison of outcomes fro ...... d-type or unknown EGFR status.
@nl
P2093
P2860
P356
P1433
P1476
The comparison of outcomes fro ...... ld-type or unknown EGFR status
@en
P2093
Agata Laudani
Alessandro Russo
Antonio Picone
Antonio Russo
Claudia Celesia
Elisabetta Gambale
Francesco Passiglia
Giovanni Sortino
Giuseppe Bronte
Giuseppina Savio
P2860
P304
35803-35812
P356
10.18632/ONCOTARGET.8130
P407
P577
2016-03-16T00:00:00Z